Perflutren Lipid Microsphere Intravenous Suspension
Brain Tumor, Primary
Sunnybrook Health Sciences CentrePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Brain Tumor, Primary cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rvp-001 Reveal Pharmaceuticals Inc. | Phase 2 | B |
5-ala Constantinos Hadjipanayis | Phase 2 | CCC |
Capecitabine Northwell Health | Phase 1/2 | CCC |
Eloxatin Northwell Health | Phase 1/2 | CCC |
Paltimatrectinib Pyramid Biosciences | Phase 1 | CC |
Definity Sunnybrook Health Sciences Centre | Phase 1 | CC |
Voluven National Taiwan University Hospital | N/A | D |
Same molecule, other indications
Perflutren Lipid Microsphere Intravenous Suspension is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →